北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学精神卫生研究所  > 期刊论文
学科主题: 精神卫生
题名:
Citalopram in the treatment of depressive disorders: an open label, multicenter study in China
作者: Si, Tianmei; Shu, Liang
关键词: Antidepressant ; citalopram ; depression ; selective serotonin reuptake inhibitor
刊名: AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY
发表日期: 2008-05-01
卷: 2, 期:3, 页:59-65
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Pharmacology & Pharmacy
研究领域[WOS]: Pharmacology & Pharmacy
关键词[WOS]: SEROTONIN REUPTAKE INHIBITORS ; MAJOR DEPRESSION ; NEWER ANTIDEPRESSANTS ; DRUG-INTERACTIONS ; HUMAN CYTOCHROMES ; GENERAL-PRACTICE ; DOUBLE-BLIND ; PLACEBO ; THERAPY ; TRIAL
英文摘要:

Results of randomized, placebo-controlled trials with the selective serotonin reuptake inhibitor citalopram suggest that this agent is safe and effective for the treatment of depressive disorders. We investigated the safety and efficacy of citalopram in the treatment of Chinese patients with depressive disorders. An 8-week, open-label, multicenter study evaluated the safety and efficacy of citalopram in the treatment of patients with an ICD-10 diagnosis of depressive disorder or depressive episode of bipolar disorder. Efficacy measures included the Hamilton Rating Scale for Depression (HAMD) and the Clinical Global Impression (CGI). A total of 6080 patients (2553 men, 3527 women) (mean age 40.9 +/- 15.6 years, range 18 - 92) participated in the study. Mean HAMD scores decreased significantly (p < 0.001) after 2 weeks of treatment and at all subsequent study visits. Endpoint analyses showed that 89.9% of the patients demonstrated a clinical response, defined as a >= 50% reduction in HAMD scores. The mean daily dose of citalopram at endpoint was 23.65 mg. Nausea (7.6%), headache (3.7%) and dry mouth (2.9%) were the most frequently reported adverse events. Patients with bipolar depression and comorbid obsessive compulsive disorder (OCD) received a higher mean daily dose (26.4 and 27.7 mg, respectively), while patients with comorbid physical disorders received a lower dose (21.9 mg) than patients with simple depressive disorder. The results of this 8-week open-label study suggest that citalopram is safe and effective in the treatment of depression in Chinese patients. Limitations is an open-label and uncontrolled.

语种: 英语
项目资助者: Wujieping Medical Science Foundation
WOS记录号: WOS:000262373300004
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/56637
Appears in Collections:北京大学精神卫生研究所_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Inst Mental Hlth, Dept Clin Psychopharmacol, Beijing 100083, Peoples R China

Recommended Citation:
Si, Tianmei,Shu, Liang. Citalopram in the treatment of depressive disorders: an open label, multicenter study in China[J]. AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY,2008,2(3):59-65.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Si, Tianmei]'s Articles
[Shu, Liang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Si, Tianmei]‘s Articles
[Shu, Liang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace